The stock's score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. Despite strong technical indicators suggesting bullish momentum, valuation concerns due to a negative P/E ratio weigh heavily. The absence of earnings call and corporate event data limits additional insights.

Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)

Market Cap

kr452.29M

Dividend YieldN/A

Average Volume (3M)38.30K

Price to Earnings (P/E)―

Beta (1Y)0.06

Revenue Growth-12.50%

EPS Growth-783.92%

CountrySE

Employees36

SectorHealthcare

Sector Strength41

IndustryMedical - Devices

Share Statistics

EPS (TTM)-0.44

Shares Outstanding20,694,328

10 Day Avg. Volume59,262

30 Day Avg. Volume38,302

Financial Highlights & Ratios

PEG Ratio0.52

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-5.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Integrum AB Class B Business Overview & Revenue Model

Company DescriptionIntegrum AB Class B (INTEG.B) is a Swedish company specializing in developing and marketing innovative solutions for orthopedic and reconstructive surgery, focused primarily on osseointegration technology. The company is renowned for its OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System, which is designed to improve the quality of life for amputees by providing a direct connection between the prosthesis and the bone, enhancing mobility and comfort.

How the Company Makes MoneyIntegrum AB generates revenue primarily through the sale of its OPRA Implant System and related services. The company earns money by selling these advanced prosthetic solutions to healthcare providers and directly to patients globally. Additionally, Integrum engages in partnerships with medical institutions for research and development, which may also contribute to its revenue. The company leverages its expertise in osseointegration technology to expand its market presence and drive sales growth in the orthopedic and reconstructive surgery sectors.

Integrum AB Class B Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Breakdown
Income Statement		Total Revenue
90.01M	104.12M	74.27M	55.72M	43.09M	26.75M
	Gross Profit
54.83M	91.26M	60.84M	46.56M	34.89M	21.37M
	EBIT
-32.49M	6.51M	-19.70M	1.04M	-1.85M	-15.68M
	EBITDA
-22.34M	8.76M	-20.24M	2.60M	-1.59M	-14.98M
	Net Income Common Stockholders
-19.55M	4.03M	-16.18M	21.27M	-2.14M	-15.69M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.65M	16.90M	41.92M	75.34M	7.66M	13.06M
	Total Assets
180.29M	164.86M	165.17M	180.44M	37.21M	32.20M
	Total Debt
5.25M	6.42M	7.92M	580.89K	485.92K	723.80K
	Net Debt
-9.40M	-10.48M	-34.01M	-74.76M	-7.17M	-12.34M
	Total Liabilities
17.69M	22.07M	21.64M	20.70M	12.91M	8.47M
	Stockholders Equity
162.60M	142.79M	143.53M	159.74M	24.29M	23.73M
Cash Flow		Free Cash Flow
-58.94M	-24.37M	-36.50M	-49.55M	-7.47M	-19.06M
	Operating Cash Flow
-44.88M	-12.74M	-25.10M	-20.28M	-5.76M	-18.72M
	Investing Cash Flow
-14.07M	-11.63M	-11.40M	-29.27M	-1.71M	-343.68K
	Financing Cash Flow
45.23M	-648.54K	3.08M	117.23M	2.06M	21.51M

Integrum AB Class B Technical Analysis

Technical Analysis Sentiment

Positive

Last Price20.20

Price Trends

50DMA

16.02

Positive

100DMA

16.38

Positive

200DMA

20.63

Positive

Market Momentum

MACD

1.37

Negative

RSI

67.87

Neutral

STOCH

67.87

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 20.2 is above the 20-day moving average (MA) of 17.93, above the 50-day MA of 16.02, and below the 200-day MA of 20.63, indicating a bullish trend. The MACD of 1.37 indicates Negative momentum. The RSI at 67.87 is Neutral, neither overbought nor oversold. The STOCH value of 67.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
INTEG.B	53 Neutral	kr452.29M	―	-19.17%	―	-12.50%	-783.92%
BRAIN	50 Neutral	kr412.52M	―	-33.54%	―	72.05%	33.68%
DOXA	49 Neutral	kr578.49M	―	-48.55%	―	-2.22%	-295.24%
MNTC	49 Neutral	kr502.43M	―	-17.16%	―	17.75%	18.05%
ACARIX	46 Neutral	kr255.83M	―	-88.97%	―	-0.61%	54.19%
QLINEA	43 Neutral	kr282.91M	―	-159.24%	―	-22.50%	76.74%

* Healthcare Sector Average

Performance Comparison

SE:INTEG.B

Integrum AB Class B

21.20

-35.60

-62.68%

SE:ACARIX

Acarix AB

0.24

-0.09

-27.33%

SE:DOXA

Doxa AB

0.45

-0.86

-65.73%

SE:MNTC

Mentice AB

17.70

-9.30

-34.44%

SE:QLINEA

Q-linea AB

0.04

-0.59

-93.10%

SE:BRAIN

BrainCool AB

1.59

-0.73

-31.49%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.